Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2025 13:24 ET | Source: Herantis Pharma plc

Herantis Pharma presents positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease

Herantis Pharma announces positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Trial meets all primary and secondary endpoints establishing a strong...
August 26, 2025 03:00 ET | Source: PannTheraPi

PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire

PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille...
August 26, 2025 03:00 ET | Source: PannTheraPi

PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline

PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline Pre-submission...
August 21, 2025 07:30 ET | Source: Custom Market Insights

Global Non-invasive Brain Trauma Monitoring Device Market Size/Share Worth USD 32.19 Billion by 2034 at a 8.13% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)

Austin, TX, USA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Non-invasive Brain Trauma Monitoring Device Market Size, Trends and Insights By...
August 21, 2025 01:19 ET | Source: Herantis Pharma plc

Herantis Pharma releases 1H 2025 report today

Espoo, Finland, 21 August 2025: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, releases today the Company’s 1H 2025...
August 14, 2025 09:02 ET | Source: Herantis Pharma plc

Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease

Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week...
June 25, 2025 12:30 ET | Source: Custom Market Insights

[Latest] Global Cell and Gene Therapy Market Size/Share Worth USD 118.63 Billion by 2034 at a 18.79% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, June 25, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cell and Gene Therapy Market Size, Trends and Insights By Therapy Type (Cell...
May 13, 2025 02:05 ET | Source: Herantis Pharma plc

First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease

Herantis Pharma Plc – Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease HER-096 is a first-in-class agent in development for the...
April 30, 2025 11:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces New Clinical Trial of Monarch eTNS System for Treatment of ADHD in Children with Fetal Alcohol Syndrome at UCLA

Trial to be conducted at UCLA and funded by a grant from National Institute on Alcohol Abuse and Alcoholism (NIAAA)First phase of trial will enroll up to 30 children ages 8 – 12 with exposure to...
January 13, 2025 09:00 ET | Source: NeuroSigma, Inc.

Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment

ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology & Neuroscience is a multicentre, double-blind,...